These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28932638)

  • 21. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
    Hsi ED; Steinle R; Balasa B; Szmania S; Draksharapu A; Shum BP; Huseni M; Powers D; Nanisetti A; Zhang Y; Rice AG; van Abbema A; Wong M; Liu G; Zhan F; Dillon M; Chen S; Rhodes S; Fuh F; Tsurushita N; Kumar S; Vexler V; Shaughnessy JD; Barlogie B; van Rhee F; Hussein M; Afar DE; Williams MB
    Clin Cancer Res; 2008 May; 14(9):2775-84. PubMed ID: 18451245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Profile of elotuzumab and its potential in the treatment of multiple myeloma.
    Liu YC; Szmania S; van Rhee F
    Blood Lymphat Cancer; 2014 Jun; 2014(4):15-27. PubMed ID: 26005365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date.
    Weisel K
    Onco Targets Ther; 2016; 9():6037-6048. PubMed ID: 27785050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.
    Kikuchi J; Hori M; Iha H; Toyama-Sorimachi N; Hagiwara S; Kuroda Y; Koyama D; Izumi T; Yasui H; Suzuki A; Furukawa Y
    Leukemia; 2020 Jan; 34(1):180-195. PubMed ID: 31358854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic antibodies for multiple myeloma.
    Ishida T
    Jpn J Clin Oncol; 2018 Nov; 48(11):957-963. PubMed ID: 30329116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NK and T-lymphocyte Kinetics Predict Outcome in Myeloma Patients Treated With Elotuzumab, Lenalidomide Plus Dexamethasone.
    Suzuki K; Matsumoto M; Hiramatsu Y; Takezako N; Tamai Y; Suzuki K
    Cancer Diagn Progn; 2024; 4(2):97-104. PubMed ID: 38434915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells.
    Richardson K; Keam SP; Zhu JJ; Meyran D; D'Souza C; Macdonald S; Campbell K; Robbins M; Bezman NA; Todd K; Quach H; Ritchie DS; Harrison SJ; Prince HM; Trapani JA; Jenkins MR; Beavis PA; Darcy PK; Neeson PJ
    Haematologica; 2023 Jan; 108(1):83-97. PubMed ID: 35770527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment.
    Magen H; Muchtar E
    Ther Adv Hematol; 2016 Aug; 7(4):187-95. PubMed ID: 27493709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity.
    Bernard NF; Kiani Z; Tremblay-McLean A; Kant SA; Leeks CE; Dupuy FP
    Front Immunol; 2017; 8():1033. PubMed ID: 28883824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
    Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU
    J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese subjects.
    Oboshi W; Watanabe T; Matsuyama Y; Kobara A; Yukimasa N; Ueno I; Aki K; Tada T; Hosoi E
    Hum Immunol; 2016 Feb; 77(2):165-71. PubMed ID: 26582002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.
    Friend R; Bhutani M; Voorhees PM; Usmani SZ
    Drug Des Devel Ther; 2017; 11():893-900. PubMed ID: 28356715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.
    Kurdi AT; Glavey SV; Bezman NA; Jhatakia A; Guerriero JL; Manier S; Moschetta M; Mishima Y; Roccaro A; Detappe A; Liu CJ; Sacco A; Huynh D; Tai YT; Robbins MD; Azzi J; Ghobrial IM
    Mol Cancer Ther; 2018 Jul; 17(7):1454-1463. PubMed ID: 29654064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer.
    Malaer JD; Marrufo AM; Mathew PA
    Clin Immunol; 2019 Jul; 204():50-56. PubMed ID: 30347240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab.
    Postelnek J; Neely RJ; Robbins MD; Gleason CR; Peterson JE; Piccoli SP
    AAPS J; 2016 Jul; 18(4):989-99. PubMed ID: 27116021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
    Richardson PG; Jagannath S; Moreau P; Jakubowiak AJ; Raab MS; Facon T; Vij R; White D; Reece DE; Benboubker L; Zonder J; Tsao LC; Anderson KC; Bleickardt E; Singhal AK; Lonial S;
    Lancet Haematol; 2015 Dec; 2(12):e516-27. PubMed ID: 26686406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production.
    Capuano C; Pighi C; Molfetta R; Paolini R; Battella S; Palmieri G; Giannini G; Belardinilli F; Santoni A; Galandrini R
    Oncoimmunology; 2017; 6(3):e1290037. PubMed ID: 28405525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.